Literature DB >> 17060388

Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease.

Young-Hak Kim1, Seong-Wook Park, Seung-Whan Lee, Duk-Woo Park, Sung-Cheol Yun, Cheol Whan Lee, Myeong-Ki Hong, Hyun-Sook Kim, Jae-Ki Ko, Jae-Hyeong Park, Jae-Hwan Lee, Si Wan Choi, In-Whan Seong, Yoon Haeng Cho, Nae-Hee Lee, June Hong Kim, Kook-Jin Chun, Seung-Jung Park.   

Abstract

BACKGROUND: Outcomes remain relatively unfavorable for stent-based coronary intervention of lesions with long diseased segments. This study compared sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) for long coronary lesions. METHODS AND
RESULTS: The present randomized, multicenter, prospective study compared the use of long (> or =32 mm) SES with PES in 500 patients with long (> or =25 mm) native coronary lesions. The primary end point of the trial was the rate of binary in-segment restenosis according to follow-up angiography at 6 months. The SES and PES groups had similar baseline characteristics. Lesion length was 33.9+/-11.6 mm in the SES group and 34.5+/-12.6 mm in the PES group (P=0.527). The in-segment binary restenosis rate was significantly lower in the SES group than in the PES group (3.3% versus 14.6%; relative risk 0.23; P<0.001). In-stent late loss of lumen diameter was 0.09+/-0.37 mm in the SES group and 0.45+/-0.55 mm in the PES group (P<0.001). In patients with restenoses, a pattern of focal restenosis was more common in the SES group than in the PES group (100% versus 53.3%, P=0.031). Consequently, SES patients had a lower rate of target-lesion revascularization at 9 months (2.4% versus 7.2%, P=0.012). The incidence of death (0.8% in SES versus 0% in PES, P=0.499) or myocardial infarction (8.8% in SES versus 10.8% in PES, P=0.452) at 9 months of follow-up was not statistically different between the 2 groups.
CONCLUSIONS: For patients with long native coronary artery disease, SES implantation was associated with a reduced incidence of angiographic restenosis and a reduced need for target-lesion revascularization compared with PES implantation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17060388     DOI: 10.1161/CIRCULATIONAHA.106.666396

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  14 in total

1.  A prospective, multicenter, post marketing surveillance study to evaluate the safety and effectiveness of the Superia-Sirolimus Eluting Coronary Stent System (SSECSS) implanted during routine clinical practice in India.

Authors:  Praveen Chandra; Tarun Kumar
Journal:  Indian Heart J       Date:  2014-12-03

2.  Electrospun rapamycin-eluting polyurethane fibers for vascular grafts.

Authors:  Jingjia Han; Shady Farah; Abraham J Domb; Peter I Lelkes
Journal:  Pharm Res       Date:  2013-04-09       Impact factor: 4.200

3.  Prospective study to evaluate safety and efficacy of Zotarolimus Eluting Stent (PSEZES) in patients with long coronary artery lesions.

Authors:  C G Bahuleyan; V V Krishna Kumar; Shifas Babu
Journal:  Indian Heart J       Date:  2015-05-13

4.  Efficacy of sirolimus-eluting stents compared with paclitaxel-eluting stents in an unselected population with coronary artery disease: 24-month outcomes of patients in a prospective non-randomized registry in Southern Turkey.

Authors:  Davran Ciçek; Hasan Pekdemir; Nihat Kalay; Süleyman Binici; Hakan Altay; Haldun Müderrisoğlu
Journal:  Int J Med Sci       Date:  2010-06-10       Impact factor: 3.738

5.  Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries.

Authors:  Nuno M M Pires; Daniel Eefting; Margreet R de Vries; Paul H A Quax; J Wouter Jukema
Journal:  Heart       Date:  2007-04-20       Impact factor: 5.994

6.  Long-Term Predictors of Clinical Events after Off-Label Use of Drug-Eluting Stent beyond 1 Year.

Authors:  Kyeong Ho Yun; Jum Suk Ko; Sang Jae Rhee; Eun Mi Lee; Nam Jin Yoo; Nam-Ho Kim; Seok Kyu Oh; Jin-Won Jeong
Journal:  Korean Circ J       Date:  2013-03-31       Impact factor: 3.243

Review 7.  New horizons of acute myocardial infarction: from the Korea Acute Myocardial Infarction Registry.

Authors:  Ki Hong Lee; Myung Ho Jeong; Youngkeun Ahn; Myeong Chan Cho; Chong Jin Kim; Young Jo Kim
Journal:  J Korean Med Sci       Date:  2013-01-29       Impact factor: 2.153

8.  Lesion length impacts long term outcomes of drug-eluting stents and bare metal stents differently.

Authors:  Shang-Hung Chang; Chun-Chi Chen; Ming-Jer Hsieh; Chao-Yung Wang; Cheng-Hung Lee; I-Chang Hsieh
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

9.  A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease.

Authors:  Johan Bennett; Christophe Dubois
Journal:  Biologics       Date:  2013-06-19

10.  Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials.

Authors:  Sripal Bangalore; Sunil Kumar; Mario Fusaro; Nicholas Amoroso; Ajay J Kirtane; Robert A Byrne; David O Williams; James Slater; Donald E Cutlip; Frederick Feit
Journal:  BMJ       Date:  2012-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.